September 16, 2024 02:47 PM EDTUpdated 03:01 PM
Pharma
FDA+

FDA ap­proves Lil­ly's eczema drug Ebglyss for mod­er­ate-to-se­vere dis­ease

Katherine Lewin

News Reporter

Eli Lil­ly’s drug le­brik­izum­ab has been ap­proved for the treat­ment of eczema, or atopic der­mati­tis, a win for the com­pa­ny af­ter the FDA re­ject­ed the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Stem cell start­up spun out of George Church’s lab rais­es $75M

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

FDA re­jects Van­da’s treat­ment for di­ges­tion con­di­tion, com­pa­ny re­bukes agen­cy's ac­tions

Edge­wise’s stock surges as heart drug pass­es ear­ly safe­ty test

Ex­clu­sive: Flag­ship-backed Va­lo Health los­es in­ter­im CEO ahead of key Phase 2 read­out

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times